制剂

我们有一个由 1,500 多名制剂和分析研究员组成的制剂研发团队,提供从临床前到商业阶段的制剂开发和生产。我们在全球拥有一体化制剂研发和生产基地,开发各种包装形式的固体口服制剂和非口服剂型。

我们提供从实验室到大规模生产的生物利用度增强技术,如脂质纳米颗粒喷雾干燥分散体

仅在2023年,我们就支持了 1,000 多个临床前到III期的分子,验证了 40 多个后期化合物,我们还助力了 10 个制剂产品成功商业化。

制剂服务

口服制剂

非口服制剂

Analytical

Packaging, Labeling and Distribution

High Potency

赋能技术平台

lipid nanoparticle

脂质纳米颗粒
(LNP)

Spray Dried Dispersion

喷雾干燥
(SDD)

hot melt extrusion

热熔挤出
(HME)

Nano
Suspension

纳米
悬浮

liquid capsules

液体
胶囊

Why WuXi STA?

drug product thumb 制剂
Speed
Expertise
Global Quality Standard
Robust Supply
Integrated
Enabling Tech
Dont edit
Speed

8-12 weeks for IND ready formulation, 4-6 weeks from GMP API received to phase I CTM released, technology transfer to release of PPQ completed in 6 months

Team

1,400+ formulators and analytical scientists

Global Quality Standard

One quality system across all sites approved by major regulatory agencies in the world

Robust Supply

4 sites in United States, Europe and China support large scale production.

Integrated Collaboration

Formulation R&D – early phase, late phase, commercial manufacturing and analytical & QC teams work closely to streamline your projects

Enabling Technology

Lipid Nanoparticle, Spray Dried Dispersion, Hot Melt Extrusion enable your fomrmulations with enhanced solubility.

特色一体化服务

您需要帮助吗?

咨询寡核苷酸或者多肽项目?

滚动至顶部
请在浏览器中启用JavaScript来完成此表单。
Checkboxes